Cancer and its treatments are well-recognized risk factors for venous thrombo-embolism
(VTE). Although solid tumors have historically been associated with VTE, more recent data …

Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its
treatments. One in five cancer patients are estimated to develop venous and arterial events …

Cancer patients are well-known to be at increased risk of venous thromboembolism (VTE).
However, the risk varies widely between patients and over the natural history of malignancy …

Rates of venous thromboembolism (VTE) vary substantially between cancer patients.
Multiple clinical risk factors including primary site of cancer and systemic therapy, and …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …

Patients with active malignancy are well-known to be at higher risk for venous
thromboembolism (VTE). However, the risk of VTE varies considerably between patients and …

Cancer is associated with a fourfold increased risk of venous thromboembolism (VTE). The
risk of VTE varies according to the type of malignancy (ie pancreatic cancer, brain cancer …

Cancer-related venous thromboembolism (VTE) remains a major health problem,
accounting for at least 18% of all cases of VTE. Cancer patients with VTE have worse …

Venous thromboembolism (VTE) is a known complication of cancer which impacts on patient
mortality and quality of life. Despite the known deleterious effects of VTE, the benefits of …

Venous thromboembolism (VTE) represents a major challenge in the management of
patients with cancer. The malignant phenotype is associated with derangements in the …